Diabetes Podcasts > EASD 2022 Highlights Podcast
Overview
- Episode 6: Evolving landscape of type 2 diabetes management (part 2)
- Episode 5: Insulin and diabetes technology: the future is now (part 2)
- Episode 4: New insights in Incretin-based therapies (part 2)
- Episode 3: Evolving landscape of type 2 diabetes management (part 1)
- Episode 2: Insulin and diabetes technology: the future is now (part 1)
- Episode 1: New insights in Incretin-based therapies (part 1)
Episodes
Episode 6
Evolving landscape of type 2 diabetes management (part 2)
Chapter 1
Prof. Puder
Diabetologia Symposium: Remission of type 2 diabetes – fact or fiction?
Chapter 2
Dr. Kosinski
Benefits and drawbacks of early effective intervention in T2D
Chapter 3
Prof. Rudofsky
Therapy outside the box
Episode 5
Insulin and diabetes technology: the future is now (part 2)
Chapter 1
Dr. Kosinski
Fighting diabetes with tubes, scanners, and catheters
Chapter 2
Prof. Lehmann
Re-inventing the insulin experience: exploring the prospects of once-weekly insulins
Chapter 3
Prof. Lehmann
The future of multiple daily injection therapy
Episode 4
New insights in Incretin-based therapies (part 2)
Chapter 1
Dr. Gerber
Incretins: Impact on BMI
Chapter 2
Dr. Gariani
Dual incretin receptor agonists: Is GIP receptor agonism the key for success?
Chapter 3
Prof. Jornayvaz
Dual incretin receptor agonists: Is GIP receptor agonism the key for success?
Chapter 4
Prof. Nauck
INCSG Symposium: GLP-1 dual and multi-agonist peptides: which additional activities to dial in?
Episode 3
Evolving landscape of type 2 diabetes management (part 1)
Chapter 1
Prof. Jornayvaz
Glycemic targets revisited: What HbA1c goals should be followed in 2022
Chapter 2
Prof. Nauck
Remission of type 2 diabetes – fact or fiction?
Episode 2
Insulin and diabetes technology: the future is now (part 1)
Chapter 1
Dr. Fischli
Debate: Insulin-free type 2 diabetes treatment
Chapter 2
Dr. Gariani
Fighting diabetes with tubes, scanners, and catheters
Episode 1
New insights in Incretin-based therapies (part 1)
Chapter 1
Prof. Lehmann
54th Claude Bernard Lecture: An updated incretin concept for tomorrow
Chapter 2
Prof. Puder
Glucose lowering agents
Chapter 3
Dr. Gerber
Lessons from trials
This page is supported by:
Eli Lilly (Suisse) SA
Ch. des Coquelicots 16
1214 Vernier, Geneva
The content of this page is intended for Swiss physicians.
For further information on our Lilly products and therapeutic areas, please contact our Medical Information:
Service hours: Monday-Friday, 8:30-15:00 hrs
Phone: +41 44 654 57 52
E-Mail: ch_medinfo@lilly.com
PP-TR-CH-0197/10.2023